slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
202,861-202,920 of 319,975
17
The slide presents two distinct clinical metrics: a box plot for arginine levels and a bar chart for patient response rates.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
19
The slide uses a heatmap to visualize individual patient outcomes, highlighting clinical improvement vs. worsening.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
23
Contains company logo, address, and website.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Includes a Kaplan-Meier survival curve and a comparative table of clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/kg dose.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
27
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to support the clinical hypothesis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
28
Includes histological images of liver tissue and a dot plot for bone mineral density (BMD).Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
Data presented includes age, sex, and region for a total N=32.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
30
The table displays mean/SD and median/range for Plasma Arginine, GMFM-E, and 2MWT, and counts/percentages for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
31
Box plot visualization of clinical trial results.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
32
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
Includes a study design timeline and MCID reference lines for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
The slide outlines standard clinical outcome assessments (COAs) for motor function.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
35
The slide uses a flow diagram to illustrate the randomization process and study timeline.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
36
The table highlights specific clinical response metrics for six individual patients, demonstrating improvements and normalization of mobility scores.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
37
The slide uses a 2x2 matrix to describe the launch strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Attention1 hit
02
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Attention1 hit
03
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Attention1 hit
04
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
05
Includes footnotes regarding non-GAAP reconciliation and royalty revenue impacts from Janssen license agreement.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
06
Includes a highlighted column for Q1'23 and detailed footnotes regarding product licensing and arbitration.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
07
The slide includes a disclaimer regarding the date of the expectations and a note about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
08
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
09
The chart illustrates the revenue contribution of four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
10
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
11
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
12
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
13
The chart includes a vertical dashed line separating 2021 from 2022.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
14
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
15
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
16
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
17
The slide outlines a two-stage clinical development strategy with specific objectives and assessment criteria for each phase.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
18
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
19
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
20
The table reconciles GAAP net loss of $180M to non-GAAP net income of $20M using various non-cash and one-time adjustments.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
21
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Action1 hit
01
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
02
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
03
The slide includes a footnote explaining F/X adjusted metrics.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
04
The slide uses TTM (Trailing Twelve-Month) metrics to show sales trends and composition.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
05
The chart includes a callout bubble highlighting the growth rate.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
06
The chart shows a decline in operating income over the trailing twelve-month periods.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
07
The chart illustrates financial performance over five quarters, with a specific footnote explaining the impact of Rivian Automotive investment valuation changes.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
08
The slide includes a footnote explaining the impact of Rivian Automotive investment valuation changes on the net income figures.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit
09
The slide uses a dual-chart layout to compare revenue growth against operating profitability.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Segment Results1 hit
10
TTM figures provided at the bottom.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Segment Results1 hit
11
TTM figures provided at the bottom.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Segment Results1 hit
12
The chart shows negative cash flow values improving over time.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Long-Term GoalLoop · Cost Of Inaction1 hit
13
The chart displays negative values (outflows) narrowing over time, indicating improved cash flow performance.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Long-Term GoalLoop · Cost Of Inaction1 hit
14
The chart displays negative values (cash outflows/investments) narrowing over time.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Long-Term GoalLoop · Cost Of Inaction1 hit
15
The chart highlights the stability of share counts over time, supporting the goal of managing dilution.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
16
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
17
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
18
Page number 18.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit